CC BY
26New concepts in ANCA detection and disease classification in small vessel vasculitis: the role of ANCA antigen specificity
Elena Csernok
Mediterr J Rheumatol 2018; 29(1):17-20
mediterranean journal
of RHEUMATOLOGY
s-ISSN: 2529-198X
E-ISSN: 2529-198X
MEDITERRANEAN JOURNAL OF RHEUMATOLOGY March 2018 | Volume 29 | Issue 1
GCsernok E
This work is licensed under and Creative Commons Attribution-NonCommercial 4.0 International License.
©CD®
MINI REVIEW
New concepts in ANCA detection and disease classification in small vessel vasculitis: the role of ANCA antigen specificity
Elena Csernok
Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany
ABSTRACT
Anti-neutrophil cytoplasmic antibodies (ANCA) play a central role in the diagnosis and pathogenesis of patients with ANCA-associated vasculitis. ANCA-associated vasculitis is a rare disease characterized by necrotizing inflammation of small/medium-sized blood vessels with and without granuloma in different organs. The main syndromes are granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic GPA. ANCA in these diseases are almost always directed against proteinase 3 and myeloperoxidase. Most laboratories worldwide use as standard the indirect immunofluorescence technique to screen for ANCA and then confirm positive I FT results with antigen specific immunoassyas for PR3- and MPO-ANCA. New guidelines for ANCA testing have been developed based on a recent European multicentre study, and according to the revised 2017 international consensus recommendations, testing for ANCA in small vessel vasculitis can be done by PR3- and MPO-ANCA immunoassays, without the categorical need for IIF. The new testing strategy for ANCA in vasculitis directly identifies the ANCA target antigen and has a particular value for the AAV sub-classification. Recent studies have shown that AAV can be classified based on ANCA serotype. ANCA presence and the antigen specificity also may have important value as a prognostic factor and may serve as a guide for immunosuppressive therapy. The clinical utility of ANCA depends on the type of assay performed and the appropiate ordering of testing the right clinical setting. Accurate identification of all patients with AAV and the avoidance of misdiagnosis can be achieved using a "gating policy" based on clinical information given to the laboratory at the time of request.
Mediterr J Rheumatol 2018; 29(1): 17-20 doi10.31138/mjr.29.1.17
Article Submitted: 11.12.2017, Revised Form 07.01.2018, Accepted 19.01.2018
Keywords: proteinase 3-, myeloperoxidase-ANCA, methods, new recommendations, clinical significance
Corresponding author:
Elena Csernok, MD
Klinik für Innere Medizin, Rheumatologie und Immunologie Medius Kliniken Kirchheim
Akademisches Lehrkrankenhaus der Universität Tübingen Eugenstr. 3
Kirchheim-Teck 73230, Germany
Tel.: +4970218841450
Email: [email protected]
INTRODUCTION
The detection of anti-neutrophil cytoplasmic antibody (ANCA) as a diagnostic tool and marker of disease in Wegener's granulomatosis was described in 1985 by Van der Woude and coworkers.1 The spectrum of diseases associated with ANCA has since increased.2 Two ANCA are highly associated markers for ANCA-associated vasculitis (AAV), the latter of which includes gran-
Cite this article as: Csernok E. New concepts in ANCA detection and disease classification in small vessel vasculitis: the role of ANCA antigen 17 specificity. Mediterr J Rheumatol 2018; 29(1):17-20.
ulomatosis with polyangiitis (GPA [formerly known as Wegener's]), microscopic polyangiitis (MPA), eosinophil granulomatosis with polyangiitis (EGPA), and primary pauci-immune crescentic glomerulonephritis, namely C-ANCA synonymous with cytoplasmic fluorescence and specificity for proteinase 3 (PR3-ANCA), and P-AN-CA with perinuclear fluorescence and specificity for myeloperoxidase. However, ANCA has limited specificity as it can be demonstrated in patients with inflammatory bowel disease (IBD), autoimmune liver disease, connective tissue diseases, infections and drug-induced vascu-litis, often with multiple antigen specificities and unclear clinical significance.2,3
Detection of ANCA in vasculitis is based on primary screening by immunofluorescence test (IFT) on etha-nol-fixed neutrophils, and positive indirect immunofluo-rescence (IIF) test should always be followed by specific PR3- and MPO-ANCA immunoassays (Figure 1). Ideally all three tests should be used in each sample.4,5 Since the establishment of this consensus, many new antigen specific immunoassays have become available, and this has challenged the position of IFT in the testing algorithm for ANCA in vasculitis.6,7 Furthermore, there is a need for screening algorithm including clinical gating policies to guide the flow of analysis in diagnostic laboratories. In the right clinical context, a positive test for PR3- or MPO-ANCA has high sensitivity and specificity for a diagnosis of AAV.
This review considers current data on ANCA testing, presents the new international consensus on ANCA testing, and discusses the usefulness of PR3- and MPO-AN-CA in the diagnosing and managing of patients with small-vessel vasculitis.
Figure 1: ANCA main fluorescence patterns: C-ANCA (cytoplasmic) ANCA, P-ANCA (perinuclear) and A-ANCA (atypical) on ethanol-fixed neutrophils
PARADIGM SHIFT IN ANCA DIAGNOSTIC: NEW INTERNATIONAL CONSENSUS RECOMMENDATIONS
An international consensus statement for ANCA testing was issued in 1999 and states that "ANCA is best demonstrated by using a combination of indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISAs) that detect ANCA specific for proteinase 3 (PR3) or myeloperoxidase (MPO). For ANCA testing in "new" patients, IIF must be performed on all serum samples. Serum samples containing ANCA [...] should be tested in ELISAs for PR3-ANCA and MPO-ANCA".4 Although this consensus is still widely applied, the position of IIF is being questioned.
Over the last 15 years, the performance of ELISA has improved and novel, sensitive and automated technologies, such as fluoro-enzyme immunoassay, chemilumines-cence assay and multiplexed flow immunoassay, have been introduced. Besides, there have been advances in assay setup (antigen presentation) with development of second (capture-based) and third (anchor-based) generation assays. Largely, currently available assays for PR3-ANCA and MPO-ANCA are highly sensitive and specific for GPA and MPA.7
The availability of reliable antigen-specific immuno-as-says has raised doubts about the two-stage diagnostic strategy currently recommended for ANCA detection.6,7 In a recent European Vasculitis Study (EUVAS) multicenter study, it has been confirmed that the diagnostic performance of antigen-specific immuno-assays equaled or even exceeded the diagnostic performance of IIF.8,9 When compared to the study of Hagen and colleagues which was 20 years ago and was a major basis for the consensus statement, there have been marked improvements (mainly in specificity) of the antigen-specific immunoassays.10
Given these improvements, the revised international consensus demonstrated that high quality antigen-specific immunoassays can be used for the diagnosis of ANCA-associated vasculitis without the need for IIF.11 Furthermore, it was shown that appropriately designed reference ranges for antibody levels improve interpretation of antigen-specific immuno-assays.12 When new assays are introduced (and for assays not included in the above-mentioned international study, diagnostic performance characteristics need to be checked based on diagnostic samples of GPA/MPA patients and relevant disease controls.8,9 One needs, however, to realize that single immuno-assays never have a sensitivity and specificity of 100%. In case of a high clinical suspicion and a negative test result, a second immuno-assay or IIF can be used to increase the sensitivity. Performing a second assay or IIF can also (marginally) increase the specificity in case of (low) positive test results. Alternatively, if IIF is used as a screening assay in locally determined best
NEW CONCEPTS IN ANCA DETECTION AND DISEASE CLASSIFICATION IN SMALL VESSEL VASCULITIS:
THE ROLE OF ANCA ANTIGEN SPECIFICITY
testing algorithms, then the laboratory needs to ensure that the IIF operates at a high sensitivity as there is a large variability in performance of IIF between laboratories. Whereas PR3- and MPO-ANCA have been shown to be highly specific for AAV, their diagnostic value of non-va-sculitic conditions is very limited. An overestimation of the diagnostic relevance of a positive ANCA test may erroneously misdirect clinicians and delay adequate treatment. The diagnostic accuracy of ANCA testing in vasculitis should be improved by an increased pretest probability.11
Accurate identification of all patients with AAV and the avoidance of misdiagnosis can be achieved by use a "gating policy" based on clinical information given to the laboratory at the time of request. This policy limits requests for ANCA testing exclusively to clinical scenarios that may suggest a diagnosis of necrotizing vasculitis.11 Recently, Arnold and colleagues investigated the impact of a "gating policy" at a single regional center in the year prior to and following the consensus guidelines, and demonstrated that adherence to a "gating policy" for ANCA testing coupled with close liaison between clinician and laboratory does not result in either a missed or delayed diagnosis of AAV.13
In summary, the new recommendation is that PR3- and MPO-ANCA immunoassays can be used for accurate diagnosis of ANCA-associated vasculitis, without the need for IIF.11 The current consensus recommendation applies to ANCA testing for the diagnosis of vasculitis, but does not apply to ANCA testing for the diagnosis of inflammatory bowel disease, autoimmune liver disease or drug-induced autoimmunity.
PR3- AND MPO-ANCA ARE USEFUL TOOL FOR DISEASE CLASSIFICATION IN SMALL VESSEL VASCULITIS
Existing classification systems of small vessel vasculitis have relied on combinations of different clinical, radiographic and histological findings, but have not included ANCA specificity. Accumulating evidence suggests that ANCA specificity could be better than clinical diagnosis for defining groups of patients, as PR3- and MPO-AN-CA are associated with different genetic backgrounds, epidemiology, clinical features, histological findings, and pathogenesis. The new classification approach of AAV is to use ANCA serotypes to classify disease and provide immediate diagnosis based on the presence of PR3- and/or MPO-ANCA. It was demonstrated that serotyping distinguishes distinct classes of ANCA disease: PR3-ANCA associated Vasculitis (PR3-AAV), MPO-AN-CA associated Vasculitis (MPO-AAV) and ANCA-nega-tive Vasculitis.14
The genetic data from genome wide studies (GWAS) point to genetic differences between PR3- and MPO-ANCA patients. These studies have shown that the autoantigen
specificities PR3 and MPO correlate better with different HLA risk genes (PR3-ANCA with HLA-DP, MPO-ANCA with HLA-DQ) than with the clinical and pathological phenotypes of GPA and MPA.15 Moreover, the association with the genes encoding PR3 (PTN3) and its inhibitor a-1-antitrypsin (SERPINA1) with PR3-ANCA disease and/or GPA additionally supports a central pathogenetic role of these autoantigens and their neutralizing counter-parts.15
Clinical features differ both in the type and in frequency between PR3-AAV and MPO-AAV. PR3-AAV is associated with granulomatous inflammation, respiratory tract involvement, more extensive extra-renal organ manifestation and a higher relapse rate.16,17 In contrast, MPO-AAV is more frequent in kidney-limited disease, displays more severe renal scarring and a worse renal prognosis. Furthermore, patients with MPO-ANCAs are more likely to have renal pathology classified as mixed or sclerotic, and to have a strong association with lung fibrosis compared to patients with PR3-ANCA.1819 Among patients receiving a clinical diagnosis of GPA, those positive for MPO-ANCAs more frequently have limited disease without severe organ involvement, a higher prevalence of subglottic stenosis, a less frequent need for cyclophosphamide or rituximab therapy and fewer relapses than patients who are positive for PR3ANCA.20,21 These data indicate that ANCA specificity is a major determinant of the clinical presentation in AAV. In summary, the classification of patients by ANCA specificity (PR3-ANCAs versus MPO-ANCAs) provides practical diagnostic criteria better aligned to patient phe-notype, outcomes and treatment responses than does their classification by clinical diagnosis (GPA vs. MPA and EGPA).14
CONCLUSION
ANCA serology and the associated clinical manifestation of AAV continue to attract the attention of clinicians and investigators alike. In addition to be providing a useful diagnostic tool for small vessel vasculitis, ANCA testing may be useful in predicting relapses and in guiding therapy. The revised consensus recommendations on ANCA testing state that high quality antigen-specific immuno-assays are the preferred screening methodology for the diagnosis of ANCA-associated vasculitis. IIF is no longer deemed suitable as the first screening test, and it adds little to antigen-specific assays in the diagnosis of AN-CA-associated vasculitis when the pre-test probability of the disease is high.
Notwithstanding, any testing strategy applicable to vasculitis should be able to identify relevant ANCA target antigens (PR3 and MPO), since these correlate best with the clinicopathological aspects, disease activity, propensity for relapse, and response to therapy.
CONFLICT OF INTEREST
Dr. Csernok has been a consultant for Inova Diagnostics and has received lecture fees from Bio-Rad, Inova Diagnostics, Medipan, Menarini, Orgentec and Thermo Fisher.
REFERENCES
1. Van der Woude FJ, Rasmussen N, Lobatto S. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1:425-9.
2. Csernok E, Lamprecht P, Gross WL. Diagnostic significance of ANCA in vasculitis. Nat Clin Pract Rheumatol 2006; 2:174-5.
3. Kallenberg CGM, Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis. Rheumatology 2015; 28:1-14.
4. Savige J, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999; 111:507-13.
5. Savige J, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2013; 120:312-8.
6. Cohen Tervaert JW, Damoiseaux J. Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol 2012; 43: 211-9.
7. Csernok E, Moosig F. Current and emerging techniques for ANCA detection in vasculitis. Nat. Rev. Rheumatol 2014; 10:494-501.
8. Csernok E, et al. Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Autoimmun 2016; Rev. 15:736-41.
9. Damoiseaux J, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis 2017; 76:647-53.
10. Hagen EC, et al. Diagnostic value of standardized assays for an-ti-neutrophil cytoplasmic antibodies in idiopathic systemic vascu-litis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53:743-53.
11. Bossuyt X, et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017; doi: 10.1038/nrrheum, 2017.140. [Epub ahead of print]
12. Bossuyt X, et al. A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplas-mic antibodies. Rheumatology 2017; doi: 10.1093/rheumatolo-gy/kex170. [Epub ahead of print]
13. Arnold DF, et al. Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients. J Clin Pathol 2010; 63:678-80.
14. Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-asso-ciated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 2016; 12:570-9.
15. Lyons PA, et al. Genetically distinct subsets within ANCA-associat-ed vasculitis. N Engl J Med 2012; 367:214-23.
16. Franssen CF, et al. Antiproteinase 3- and antimyeloperoxidase-as-sociated vasculitis. Kidney Int 2000; 57:2195-206.
17. Schönermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperox-idase-ANCA. Rheumatology (Oxford) 2011; 40:178-84.
18. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noël LH, Waldherr R, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002; 61:80-9.
19. Quintana LF, Peréz NS, De Sousa E et al. ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2014; 19.
20. Lionaki S, et al. Classification of antineutrophil cytoplasmic auto-antibody vasculitides: the role of antineutrophil cytoplasmic auto-antibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64:3452-62.
21. Mahr A, et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2013; 72:1003-10.
